
Redhill Biopharma Ltd
NASDAQ:RDHL

Operating Margin
Redhill Biopharma Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
IL |
![]() |
Redhill Biopharma Ltd
NASDAQ:RDHL
|
4.6m USD |
-182%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
756.3B USD |
40%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
405.3B USD |
26%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
45%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
207.7B CHF |
33%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
179.9B CHF |
33%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
165.5B GBP |
24%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
211.1B USD |
34%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
144.6B USD |
27%
|
Redhill Biopharma Ltd
Glance View
RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Redhill Biopharma Ltd's most recent financial statements, the company has Operating Margin of -181.7%.